Characteristics and distinct prognostic determinants of individuals with hepatosplenic T-cell lymphoma over the past two decades.

IF 2.6 Q3 ONCOLOGY
Ayrton Bangolo, Pierre Fwelo, Shraboni Dey, Tanni Sethi, Sowmya Sagireddy, Jawaria Chatta, Ashish Goel, Sneha Nagpaul, Eric Pin-Shiuan Chen, Chiranjeeve Saravanan, Sheeja Gangan, Joel Thomas, Sarah Potiguara, Vignesh K Nagesh, Daniel Elias, Charlene Mansour, Prajakta H Ratnaparkhi, Priyanshu Jain, Midhun Mathew, Taylor Porter, Shadiya Sultan, Shailaja Abbisetty, Linh Tran, Megha Chawla, Abraham Lo, Simcha Weissman, Christina Cho
{"title":"Characteristics and distinct prognostic determinants of individuals with hepatosplenic T-cell lymphoma over the past two decades.","authors":"Ayrton Bangolo, Pierre Fwelo, Shraboni Dey, Tanni Sethi, Sowmya Sagireddy, Jawaria Chatta, Ashish Goel, Sneha Nagpaul, Eric Pin-Shiuan Chen, Chiranjeeve Saravanan, Sheeja Gangan, Joel Thomas, Sarah Potiguara, Vignesh K Nagesh, Daniel Elias, Charlene Mansour, Prajakta H Ratnaparkhi, Priyanshu Jain, Midhun Mathew, Taylor Porter, Shadiya Sultan, Shailaja Abbisetty, Linh Tran, Megha Chawla, Abraham Lo, Simcha Weissman, Christina Cho","doi":"10.5306/wjco.v15.i6.745","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive peripheral T-cell lymphoma with historically dismal outcomes, representing less than one percent of non-Hodgkin lymphomas. Given its rarity, the true incidence of HSTCL is unknown and most data have been extrapolated through case reports. To the best of our knowledge, the largest and most up to date study addressing the epidemiology and outcomes of patients with HSTCL in the United States covered a period from 1996 to 2014, with a sample size of 122 patients.</p><p><strong>Aim: </strong>To paint the most updated epidemiological picture of HSTCL.</p><p><strong>Methods: </strong>A total of 186 patients diagnosed with HSTCL, between 2000 and 2017, were ultimately enrolled in our study by retrieving data from the Surveillance, Epidemiology, and End Results database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of HSTCL. Variables with a <i>P</i> value < 0.01 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio of greater than 1 representing adverse prognostic factors.</p><p><strong>Results: </strong>Male gender was the most represented. HSTCL was most common in middle-aged patients (40-59) and less common in the elderly (80+). Non-Hispanic whites (60.75%) and non-Hispanic blacks (20.97%) were the most represented racial groups. Univariate Cox proportional hazard regression analysis of factors influencing all-cause mortality showed a higher OM among non-Hispanic black patients. CSM was also higher among non-Hispanic blacks and patients with distant metastasis. Multivariate Cox proportional hazard regression analysis of factors affecting CSM revealed higher mortality in patients aged 80 or older and non-Hispanic blacks.</p><p><strong>Conclusion: </strong>Overall, the outlook for this rare malignancy is very grim. In this retrospective cohort study of the United States population, non-Hispanic blacks and the elderly had a higher CSM. This data highlights the need for larger prospective studies to investigate factors associated with worse prognosis in one ethnic group, such as treatment delays, which have been shown to increase mortality in this racial/ethnic group for other cancers.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 6","pages":"745-754"},"PeriodicalIF":2.6000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212601/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i6.745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive peripheral T-cell lymphoma with historically dismal outcomes, representing less than one percent of non-Hodgkin lymphomas. Given its rarity, the true incidence of HSTCL is unknown and most data have been extrapolated through case reports. To the best of our knowledge, the largest and most up to date study addressing the epidemiology and outcomes of patients with HSTCL in the United States covered a period from 1996 to 2014, with a sample size of 122 patients.

Aim: To paint the most updated epidemiological picture of HSTCL.

Methods: A total of 186 patients diagnosed with HSTCL, between 2000 and 2017, were ultimately enrolled in our study by retrieving data from the Surveillance, Epidemiology, and End Results database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of HSTCL. Variables with a P value < 0.01 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio of greater than 1 representing adverse prognostic factors.

Results: Male gender was the most represented. HSTCL was most common in middle-aged patients (40-59) and less common in the elderly (80+). Non-Hispanic whites (60.75%) and non-Hispanic blacks (20.97%) were the most represented racial groups. Univariate Cox proportional hazard regression analysis of factors influencing all-cause mortality showed a higher OM among non-Hispanic black patients. CSM was also higher among non-Hispanic blacks and patients with distant metastasis. Multivariate Cox proportional hazard regression analysis of factors affecting CSM revealed higher mortality in patients aged 80 or older and non-Hispanic blacks.

Conclusion: Overall, the outlook for this rare malignancy is very grim. In this retrospective cohort study of the United States population, non-Hispanic blacks and the elderly had a higher CSM. This data highlights the need for larger prospective studies to investigate factors associated with worse prognosis in one ethnic group, such as treatment delays, which have been shown to increase mortality in this racial/ethnic group for other cancers.

过去二十年来肝脾T细胞淋巴瘤患者的特征和不同的预后决定因素。
背景:肝脾T细胞淋巴瘤(HSTCL肝脾T细胞淋巴瘤(HSTCL)是一种罕见的侵袭性外周T细胞淋巴瘤,历来疗效不佳,在非霍奇金淋巴瘤中的比例不到1%。鉴于其罕见性,HSTCL 的真实发病率尚不清楚,大多数数据都是通过病例报告推断出来的。据我们所知,美国规模最大、最新的一项关于 HSTCL 患者流行病学和预后的研究涵盖了 1996 年至 2014 年期间,样本量为 122 例患者:我们从监测、流行病学和最终结果数据库中检索数据,最终将 2000 年至 2017 年期间确诊为 HSTCL 的 186 名患者纳入研究。我们分析了HSTCL的人口统计学、临床特征、总死亡率(OM)以及癌症特异性死亡率(CSM)。在单变量考克斯回归中P值小于0.01的变量被纳入多变量考克斯模型,以确定独立的预后因素,危险比大于1代表不良预后因素:男性患者最多。HSTCL在中年患者(40-59岁)中最常见,在老年人(80岁以上)中较少见。非西班牙裔白人(60.75%)和非西班牙裔黑人(20.97%)是最常见的种族群体。对影响全因死亡率的因素进行的单变量考克斯比例危险回归分析表明,非西班牙裔黑人患者的 OM 值较高。非西班牙裔黑人和远处转移患者的 CSM 也较高。对影响CSM的因素进行的多变量考克斯比例危险回归分析显示,80岁或80岁以上的患者和非西班牙裔黑人的死亡率较高:总的来说,这种罕见恶性肿瘤的前景非常黯淡。在这项针对美国人口的回顾性队列研究中,非西班牙裔黑人和老年人的 CSM 较高。这一数据突出表明,有必要进行更大规模的前瞻性研究,以调查与某一种族群体预后较差有关的因素,如治疗延迟,而治疗延迟已被证明会增加该种族/族裔群体其他癌症的死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信